Five Prime Therapeutics Inc. (NASDAQ:FPRX) reached a new 52-week high during trading on Thursday . The stock traded as high as $50.39 and last traded at $49.27, with a volume of 240,265 shares. The stock had previously closed at $49.98.

A number of equities research analysts have issued reports on FPRX shares. Credit Suisse Group AG reiterated a “buy” rating on shares of Five Prime Therapeutics in a research note on Tuesday, July 12th. Zacks Investment Research upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Tuesday, April 5th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $48.00 price target on shares of Five Prime Therapeutics in a research note on Thursday, May 19th. Leerink Swann reiterated a “buy” rating and issued a $45.00 price target on shares of Five Prime Therapeutics in a research note on Friday, July 15th. Finally, BMO Capital Markets started coverage on Five Prime Therapeutics in a research note on Tuesday, April 12th. They issued a “market perform” rating and a $50.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $45.67.

The stock has a market capitalization of $1.30 billion and a PE ratio of 5.44. The firm’s 50-day moving average price is $43.23 and its 200 day moving average price is $39.93.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.22. The company had revenue of $6.50 million for the quarter, compared to analyst estimates of $5.26 million. During the same quarter in the previous year, the firm posted ($0.44) earnings per share. The company’s quarterly revenue was up 51.2% on a year-over-year basis. Equities research analysts forecast that Five Prime Therapeutics Inc. will post ($2.35) EPS for the current year.

In related news, Director Peder Jensen sold 12,195 shares of the business’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total transaction of $603,652.50. Following the completion of the transaction, the director now directly owns 12,195 shares in the company, valued at $603,652.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

A number of hedge funds and institutional investors have bought and sold shares of FPRX. ProShare Advisors LLC increased its position in Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock worth $1,055,000 after buying an additional 3,682 shares in the last quarter. Marshall Wace LLP increased its position in Five Prime Therapeutics by 43.0% in the fourth quarter. Marshall Wace LLP now owns 237,141 shares of the company’s stock worth $9,841,000 after buying an additional 71,262 shares in the last quarter. California State Teachers Retirement System increased its position in Five Prime Therapeutics by 7.3% in the fourth quarter. California State Teachers Retirement System now owns 42,025 shares of the company’s stock worth $1,744,000 after buying an additional 2,842 shares in the last quarter. Finally, Russell Frank Co acquired a new position in Five Prime Therapeutics during the fourth quarter worth about $1,265,000.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.